secwatch.observer — SEC 8-K summary
======================================

Issuer:     Paysign, Inc. (PAYS)
CIK:        0001496443
Form:       8-K
Filed at:   2025-08-05T23:59:59+00:00
Accession:  0001683168-25-005668
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Paysign Q2 revenue $19.08M (+33%), net income $1.39M (+99%), raises FY2025 guidance
--------------------------------------------------------------------------------

- Q2 revenue $19.08M (+33.1% YoY), net income $1.39M (+99.1%), diluted EPS $0.02; Adj. EBITDA $4.51M (+101.8%), $0.08 per share.
- Pharma patient affordability revenue surged 189.9% to 40.6% of total; added 7 net programs, now 97 active.
- Added 123 net plasma centers in Q2, exiting with 607; plasma revenue down 4.7% due to industry oversupply.
- FY2025 guidance raised: revenue $76.5-78.5M, net income $6-7M ($0.10-0.12 diluted EPS), Adj. EBITDA $18-20M.
- Q3 2025 guidance: revenue $19.5-20.5M, gross margin ~59%, Adj. EBITDA $4.5-5.0M.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1496443/000168316825005668/0001683168-25-005668-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1496443/000168316825005668/paysign_8k.htm
  HTML page:      https://secwatch.observer/filing/0001683168-25-005668

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer